301246 宏源药业
午间休市 09-16 11:30:00
资讯
新帖
简况
宏源药业：将持续强化公司核心竞争力
证券之星 · 09-15 08:57
宏源药业：将持续强化公司核心竞争力
宏源药业（301246）披露2025年限制性股票激励计划首次授予部分第一个归属期归属条件成就的公告，9月14日股价上涨1.23%
证券之星 · 09-14 17:50
宏源药业（301246）披露2025年限制性股票激励计划首次授予部分第一个归属期归属条件成就的公告，9月14日股价上涨1.23%
股市必读：宏源药业新发布《第五届董事会第四次会议决议公告》
证券之星 · 09-14 02:04
股市必读：宏源药业新发布《第五届董事会第四次会议决议公告》
宏源药业：公司将持续推进高端原料药、特色医药中间体和医药制剂产品的一体化发展
证券之星 · 09-09
宏源药业：公司将持续推进高端原料药、特色医药中间体和医药制剂产品的一体化发展
宏源药业：公司已制定《市值管理制度》
证券之星 · 09-04
宏源药业：公司已制定《市值管理制度》
宏源药业：2026年第二季度公司经营业绩环比出现阶段性下滑
证券之星 · 09-02
宏源药业：2026年第二季度公司经营业绩环比出现阶段性下滑
宏源药业（301246）2026年中报简析：营收净利润同比双双增长，应收账款上升
证券之星 · 08-29
宏源药业（301246）2026年中报简析：营收净利润同比双双增长，应收账款上升
宏源药业（301246）披露2026年半年度报告，8月28日股价下跌7.67%
证券之星 · 08-28
宏源药业（301246）披露2026年半年度报告，8月28日股价下跌7.67%
宏源药业(301246)6月30日股东户数3.07万户，较上期减少4.22%
证券之星 · 08-28
宏源药业(301246)6月30日股东户数3.07万户，较上期减少4.22%
股市必读：宏源药业新发布《第五届董事会第三次会议决议公告》
证券之星 · 08-28
股市必读：宏源药业新发布《第五届董事会第三次会议决议公告》
图解宏源药业中报：第二季度单季净利润同比增长180.91%
证券之星 · 08-28
图解宏源药业中报：第二季度单季净利润同比增长180.91%
宏源药业（301246）披露签订募集资金四方监管协议公告，8月17日股价上涨2.44%
证券之星 · 08-17
宏源药业（301246）披露签订募集资金四方监管协议公告，8月17日股价上涨2.44%
宏源药业：持续推进高端原料药、特色医药中间体和医药制剂产品的一体化发展
证券之星 · 08-04
宏源药业：持续推进高端原料药、特色医药中间体和医药制剂产品的一体化发展
股市必读：宏源药业（301246）7月28日董秘有最新回复
证券之星 · 07-29
股市必读：宏源药业（301246）7月28日董秘有最新回复
宏源药业：武穴宏源锂电新能源材料一体化项目分两期建设
证券之星 · 07-28
宏源药业：武穴宏源锂电新能源材料一体化项目分两期建设
宏源药业（301246）披露更换持续督导保荐代表人公告，7月22日股价下跌2.0%
证券之星 · 07-22
宏源药业（301246）披露更换持续督导保荐代表人公告，7月22日股价下跌2.0%
宏源药业：目前该项目研发正在按计划顺利推进各项工作
证券之星 · 07-15
宏源药业：目前该项目研发正在按计划顺利推进各项工作
股市必读：宏源药业（301246）7月14日董秘有最新回复
证券之星 · 07-15
股市必读：宏源药业（301246）7月14日董秘有最新回复
宏源药业：乙醛酸产品市场占有率处于行业领先地位
证券之星 · 07-14
宏源药业：乙醛酸产品市场占有率处于行业领先地位
股市必读：宏源药业（301246）7月9日披露最新机构调研信息
证券之星 · 07-10
股市必读：宏源药业（301246）7月9日披露最新机构调研信息
加载更多
公司概况
公司名称：
湖北省宏源药业科技股份有限公司
所属行业：
医药制造业
上市日期：
2023-03-20
主营业务：
湖北省宏源药业科技股份有限公司的主营业务是有机化学原料、医药中间体、原料药、新能源及医药制剂的研发、生产和销售。公司的主要产品是乙二醛、乙醛酸、2-甲基-5-硝基咪唑、甲硝唑、鸟嘌呤、六氟磷酸锂。公司多项技术经鉴定达到国内领先或国际先进水平，并获得过多项省级科技进步奖。
发行价格：
50.00
{"stockData":{"symbol":"301246","market":"SZ","secType":"STK","nameCN":"宏源药业","latestPrice":17.44,"timestamp":1789530441000,"preClose":17.15,"halted":0,"volume":2482787,"delay":0,"changeRate":0.0169,"floatShares":173000000,"shares":400000000,"eps":0.7028,"marketStatus":"午间休市","change":0.29,"latestTime":"09-16 11:30:00","open":17.11,"high":17.45,"low":16.9,"amount":42589000,"amplitude":0.0321,"askPrice":17.45,"askSize":2,"bidPrice":17.44,"bidSize":45,"shortable":0,"etf":0,"ttmEps":0.7028,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789534800000},"marketStatusCode":3,"adr":0,"adjPreClose":17.15,"symbolType":"stock","openAndCloseTimeList":[[1789522200000,1789529400000],[1789534800000,1789542000000]],"highLimit":18.87,"lowLimit":15.43,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":400006800,"isCdr":false,"pbRate":1.49,"roa":"--","peRate":24.815026,"roe":"3.44%","epsLYR":0.2999,"committee":-0.776658,"marketValue":6976000000,"turnoverRate":0.0144,"status":0,"floatMarketCap":3016000000},"requestUrl":"/m/hq/s/301246/","defaultTab":"news","newsList":[{"id":"2667769262","title":"宏源药业：将持续强化公司核心竞争力","url":"https://stock-news.laohu8.com/highlight/detail?id=2667769262","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667769262?lang=zh_cn&edition=full","pubTime":"2026-09-15 08:57","pubTimestamp":1789433828,"startTime":"0","endTime":"0","summary":"证券之星消息，宏源药业09月14日在投资者关系平台上答复投资者关心的问题。公司将一如既往做好主营业务，持续强化公司核心竞争力，并致力于为广大投资者积极创造价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091500007068.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301246","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667652141","title":"宏源药业（301246）披露2025年限制性股票激励计划首次授予部分第一个归属期归属条件成就的公告，9月14日股价上涨1.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2667652141","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667652141?lang=zh_cn&edition=full","pubTime":"2026-09-14 17:50","pubTimestamp":1789379458,"startTime":"0","endTime":"0","summary":"截至2026年9月14日收盘，宏源药业报收于17.35元，较前一交易日上涨1.23%，最新总市值为69.4亿元。该股当日开盘16.96元，最高17.56元，最低16.93元，成交额达8849.04万元，换手率为2.95%。公告显示，公司于2026年9月10日召开董事会，审议通过2025年限制性股票激励计划首次授予部分第一个归属期归属条件成就的议案。公司层面2025年度营业收入考核完成度为84.3%，归属比例据此确定。本次归属不影响公司总股本，但将减少公司回购专用账户股份数量。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400024100.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301246","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667680117","title":"股市必读：宏源药业新发布《第五届董事会第四次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2667680117","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667680117?lang=zh_cn&edition=full","pubTime":"2026-09-14 02:04","pubTimestamp":1789322655,"startTime":"0","endTime":"0","summary":"关于聘任财务负责人的公告宏源药业于2026年9月10日召开第五届董事会第四次会议，聘任谢广化为公司财务负责人，任期自董事会审议通过之日起至第五届董事会任期届满；谢广化未持有公司股份，已获授予尚未归属限制性股票80,000股，与控股股东、实际控制人等无关联关系，未受过行政处罚或监管惩戒。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400000825.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301246","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666305690","title":"宏源药业：公司将持续推进高端原料药、特色医药中间体和医药制剂产品的一体化发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2666305690","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666305690?lang=zh_cn&edition=full","pubTime":"2026-09-09 08:42","pubTimestamp":1788914536,"startTime":"0","endTime":"0","summary":"证券之星消息，宏源药业09月08日在投资者关系平台上答复投资者关心的问题。宏源药业回复：您好，1、公司“年产7000吨碳酸亚乙烯酯新建项目”正按计划稳步推进，具体进展及完工投产时间，请关注公司的有关信息披露。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900007802.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","09939","301246","BK0239","BK1161","BK1574","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664333429","title":"宏源药业：公司已制定《市值管理制度》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664333429","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664333429?lang=zh_cn&edition=full","pubTime":"2026-09-04 20:48","pubTimestamp":1788526101,"startTime":"0","endTime":"0","summary":"证券之星消息，宏源药业09月03日在投资者关系平台上答复投资者关心的问题。公司已制定《市值管理制度》，高度重视市值管理工作。后续如有回购等相关计划，公司将严格按照相关规定履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400039138.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301246"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664474893","title":"宏源药业：2026年第二季度公司经营业绩环比出现阶段性下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2664474893","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664474893?lang=zh_cn&edition=full","pubTime":"2026-09-02 11:36","pubTimestamp":1788320198,"startTime":"0","endTime":"0","summary":"证券之星消息，宏源药业(301246)09月01日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，半年报显示出来Q2比Q1利润下降了九成，请问是为什么呢？？盈利能力急剧下降能否解释一下原因？宏源药业回复：您好，2026年第二季度公司经营业绩环比出现阶段性下滑，主要受两方面因素共同影响，一是六氟磷酸锂第二季度均价环比有所回落；二是核心原材料碳酸锂等采购价格阶段性环比上涨，两端因素共同挤压了公司当期盈利水平。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200016953.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301246","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663016231","title":"宏源药业（301246）2026年中报简析：营收净利润同比双双增长，应收账款上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2663016231","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663016231?lang=zh_cn&edition=full","pubTime":"2026-08-29 06:51","pubTimestamp":1787957495,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期宏源药业发布2026年中报。截至本报告期末，公司营业总收入13.42亿元，同比上升52.05%，归母净利润1.56亿元，同比上升2788.93%。按单季度数据看，第二季度营业总收入6.38亿元，同比上升42.15%，第二季度归母净利润1189.06万元，同比上升180.91%。本报告期宏源药业应收账款上升，应收账款同比增幅达76.57%。本文数据来源于宏源药业2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082900013197.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301246"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662069191","title":"宏源药业（301246）披露2026年半年度报告，8月28日股价下跌7.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662069191","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662069191?lang=zh_cn&edition=full","pubTime":"2026-08-28 18:00","pubTimestamp":1787911249,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，宏源药业报收于19.75元，较前一交易日下跌7.67%，最新总市值为79亿元。该股当日开盘20.11元，最高20.19元，最低19.28元，成交额达3.83亿元，换手率为11.2%。宏源药业于2026年8月28日披露《2026年半年度报告》。报告显示，本报告期营业收入为1,341,942,986.85元，归属于上市公司股东的净利润为156,238,212.74元，扣除非经常性损益后的净利润为159,473,654.83元，经营活动产生的现金流量净额为39,516,780.40元。本报告期末总资产为6,409,597,909.06元，归属于上市公司股东的净资产为4,604,751,211.85元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800042066.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301246"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662069549","title":"宏源药业(301246)6月30日股东户数3.07万户，较上期减少4.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662069549","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662069549?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:57","pubTimestamp":1787911021,"startTime":"0","endTime":"0","summary":"证券之星消息，近日宏源药业披露，截至2026年6月30日公司股东户数为3.07万户，较3月31日减少1350.0户，减幅为4.22%。在化学制药行业个股中，宏源药业股东户数低于行业平均水平，截至6月30日，化学制药行业平均股东户数为3.67万户。从股价来看，2026年3月31日至2026年6月30日，宏源药业区间涨幅为16.61%，在此期间股东户数减少1350.0户，减幅为4.22%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800041823.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301246","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662036423","title":"股市必读：宏源药业新发布《第五届董事会第三次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2662036423","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662036423?lang=zh_cn&edition=full","pubTime":"2026-08-28 06:09","pubTimestamp":1787868574,"startTime":"0","endTime":"0","summary":"截至2026年8月27日收盘，宏源药业报收于21.39元，上涨0.99%，换手率5.38%，成交量9.14万手，成交额1.92亿元。公司公告汇总：宏源药业于8月26日召开第五届董事会第三次会议，审议通过《2026年半年度报告》及其摘要、《2026年半年度募集资金存放、管理与使用情况专项报告》。董事会认为半年度报告真实、准确、完整，募集资金使用符合相关规定，无违规情形。相关报告已在巨潮资讯网披露。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800010552.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301246"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662087023","title":"图解宏源药业中报：第二季度单季净利润同比增长180.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662087023","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662087023?lang=zh_cn&edition=full","pubTime":"2026-08-28 03:03","pubTimestamp":1787857385,"startTime":"0","endTime":"0","summary":"证券之星消息，宏源药业2026年中报显示，上半年度公司主营收入13.42亿元，同比上升52.05%；归母净利润1.56亿元，同比上升2788.93%；扣非净利润1.59亿元，同比上升838.6%；其中2026年第二季度，公司单季度主营收入6.38亿元，同比上升42.15%；单季度归母净利润1189.06万元，同比上升180.91%；单季度扣非净利润612.31万元，同比上升127.45%；负债率28.18%，投资收益3807.34万元，财务费用747.98万元，毛利率23.07%。财报数据概要请见下图:本文数据来源于宏源药业2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800006207.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301246"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660642435","title":"宏源药业（301246）披露签订募集资金四方监管协议公告，8月17日股价上涨2.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660642435","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660642435?lang=zh_cn&edition=full","pubTime":"2026-08-17 22:33","pubTimestamp":1786977198,"startTime":"0","endTime":"0","summary":"截至2026年8月17日收盘，宏源药业报收于21.79元，较前一交易日上涨2.44%，最新总市值为87.16亿元。该股当日开盘21.3元，最高21.81元，最低21.05元，成交额达1.7亿元，换手率为4.63%。宏源药业于2026年8月17日披露《关于签订募集资金四方监管协议的公告》。公司、湖北省宏源氟化工有限责任公司与中信银行武汉分行、保荐机构国联民生证券承销保荐有限公司已签订募集资金四方监管协议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700035789.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301246"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656253523","title":"宏源药业：持续推进高端原料药、特色医药中间体和医药制剂产品的一体化发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2656253523","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656253523?lang=zh_cn&edition=full","pubTime":"2026-08-04 16:21","pubTimestamp":1785831675,"startTime":"0","endTime":"0","summary":"证券之星消息，宏源药业08月04日在投资者关系平台上答复投资者关心的问题。未来，公司将持续推进高端原料药、特色医药中间体和医药制剂产品的一体化发展，同时进一步拓展国际市场，并在国内市场大力推进仿制药的报批，不断丰富公司医药产品管线，提升医药板块的业务规模和市场竞争力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400026663.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK1515","BK1161","301246","09939","BK0239","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655013889","title":"股市必读：宏源药业（301246）7月28日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2655013889","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655013889?lang=zh_cn&edition=full","pubTime":"2026-07-29 01:08","pubTimestamp":1785258494,"startTime":"0","endTime":"0","summary":"截至2026年7月28日收盘，宏源药业报收于19.09元，下跌1.75%，换手率7.59%，成交量12.91万手，成交额2.52亿元。董秘最新回复投资者： 贵公司董秘你好，公司武穴项目扩产何时投产？目前建设进度如何？公司7000吨vc电解液计划何时投产？","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072900000947.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301246"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654072155","title":"宏源药业：武穴宏源锂电新能源材料一体化项目分两期建设","url":"https://stock-news.laohu8.com/highlight/detail?id=2654072155","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654072155?lang=zh_cn&edition=full","pubTime":"2026-07-28 16:30","pubTimestamp":1785227433,"startTime":"0","endTime":"0","summary":"证券之星消息，宏源药业(301246)07月28日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司董秘你好，公司武穴项目扩产何时投产？目前建设进度如何？公司7000吨vc电解液计划何时投产？宏源药业回复：您好，“武穴宏源锂电新能源材料一体化项目“分两期建设，计划在一期建设投产一年后再开始二期建设，目前一期建设正在设计和规划阶段。“年产7000吨碳酸亚乙烯酯新建项目”正在建设中，具体进展及完工投产时间，请关注公司的有关信息披露。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072800026221.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["399941","160640","159875","301246","BK0239","000941.SH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653876684","title":"宏源药业（301246）披露更换持续督导保荐代表人公告，7月22日股价下跌2.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653876684","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653876684?lang=zh_cn&edition=full","pubTime":"2026-07-22 22:20","pubTimestamp":1784730040,"startTime":"0","endTime":"0","summary":"截至2026年7月22日收盘，宏源药业报收于18.14元，较前一交易日下跌2.0%，最新总市值为72.56亿元。宏源药业于近日披露《关于更换持续督导保荐代表人的公告》。公告显示，公司收到国联民生证券承销保荐有限公司函件，因原持续督导保荐代表人谢广化先生工作变动，不再担任公司持续督导保荐代表人，由肖舜华女士接替其职务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200047434.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301246"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651455971","title":"宏源药业：目前该项目研发正在按计划顺利推进各项工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2651455971","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651455971?lang=zh_cn&edition=full","pubTime":"2026-07-15 16:51","pubTimestamp":1784105470,"startTime":"0","endTime":"0","summary":"证券之星消息，宏源药业(301246)07月15日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵司研发的硫化物固态电解质项目进展顺利吗？宏源药业回复：您好，目前该项目研发正在按计划顺利推进各项工作。感谢您的关注本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500031586.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301246"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651483405","title":"股市必读：宏源药业（301246）7月14日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2651483405","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651483405?lang=zh_cn&edition=full","pubTime":"2026-07-15 02:05","pubTimestamp":1784052312,"startTime":"0","endTime":"0","summary":"截至2026年7月14日收盘，宏源药业报收于21.53元，上涨1.13%，换手率5.32%，成交量9.04万手，成交额1.92亿元。交易信息汇总资金流向7月14日主力资金净流入708.17万元；游资资金净流入1255.75万元；散户资金净流出1963.92万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500002343.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301246","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651175020","title":"宏源药业：乙醛酸产品市场占有率处于行业领先地位","url":"https://stock-news.laohu8.com/highlight/detail?id=2651175020","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651175020?lang=zh_cn&edition=full","pubTime":"2026-07-14 16:57","pubTimestamp":1784019431,"startTime":"0","endTime":"0","summary":"证券之星消息，宏源药业(301246)07月14日在投资者关系平台上答复投资者关心的问题。投资者提问：乙醛酸是贵公司主要产品之一，我想了解贵公司这一产品市场占有率是多少，开工率如何，今年价格趋势如何？宏源药业回复：您好，公司乙醛酸产品的市场占有率处于行业领先地位，产品目前生产经营稳定，满产满销，产品销售价格随着市场行情，供需状况等多种因素影响，具体数据情况请关注公司后续定期报告。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071400031699.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301246"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650976781","title":"股市必读：宏源药业（301246）7月9日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2650976781","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650976781?lang=zh_cn&edition=full","pubTime":"2026-07-10 01:46","pubTimestamp":1783619171,"startTime":"0","endTime":"0","summary":"截至2026年7月9日收盘，宏源药业报收于22.63元，下跌2.67%，换手率7.78%，成交量13.23万手，成交额2.98亿元。当日关注点交易信息汇总：7月9日主力资金净流出464.59万元，游资资金净流入1041.09万元。机构调研要点7月9日湖北辖区上市公司2026年投资者集体接待日活动公司六氟磷酸锂产品生产、销售正常，处于满产满销状态。“6000吨/年产高纯晶体六氟磷酸锂改扩建项目”目前处于试生产阶段。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000001031.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301246","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1789530498443,"stockEarnings":[{"period":"1week","weight":-0.0561},{"period":"1month","weight":-0.1937},{"period":"3month","weight":-0.3833},{"period":"6month","weight":-0.1461},{"period":"1year","weight":0.1439},{"period":"ytd","weight":-0.3128}],"compareEarnings":[{"period":"1week","weight":-0.0194},{"period":"1month","weight":-0.016},{"period":"3month","weight":-0.0593},{"period":"6month","weight":-0.0355},{"period":"1year","weight":0.001},{"period":"ytd","weight":-0.0263}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"湖北省宏源药业科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"30668人(较上一季度减少4.22%)","perCapita":"5639股","listingDate":"2023-03-20","address":"湖北省黄冈市罗田县凤山镇经济开发区宏源路8号","registeredCapital":"40000万元","survey":" 湖北省宏源药业科技股份有限公司的主营业务是有机化学原料、医药中间体、原料药、新能源及医药制剂的研发、生产和销售。公司的主要产品是乙二醛、乙醛酸、2-甲基-5-硝基咪唑、甲硝唑、鸟嘌呤、六氟磷酸锂。公司多项技术经鉴定达到国内领先或国际先进水平，并获得过多项省级科技进步奖。","listedPrice":50},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"宏源药业(301246)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供宏源药业(301246)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"宏源药业,301246,宏源药业股票,宏源药业股票老虎,宏源药业股票老虎国际,宏源药业行情,宏源药业股票行情,宏源药业股价,宏源药业股市,宏源药业股票价格,宏源药业股票交易,宏源药业股票购买,宏源药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"宏源药业(301246)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供宏源药业(301246)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}